Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$155.20 USD

155.20
4,328,741

-0.27 (-0.17%)

Updated Nov 11, 2024 03:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Karyopharm's Liposarcoma Candidate Superior in Phase II Study

Karyopharm's (KPTI) selinexor reduced the risk of progression or death in previously treated patients with advanced dedifferentiated liposarcoma.

    Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake

    Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.

      Here's Why These 3 Biotech Stocks Might Stop Rallying

      The momentum in the biotech sector is likely to continue. However, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant gains year to date.

        Top Research Reports for Northrop Grumman, BNY Mellon & Celgene

        Today's Research Daily features new research reports on 16 major stocks, including Northrop Grumman (NOC), Bank of New York Mellon (BK) and Celgene (CELG)

          Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia

          Alkermes (ALKS) announced encouraging results from a phase IV study of ARISTADA for the treatment of schizophrenia.

            Catalyst (CPRX) Focused on Two Lead Pipeline Candidates

            : Catalyst (CPRX) remains focused on development of its two lead pipeline candidates, Firdapse and CPP-115.

              J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU

              J&J's (JNJ) pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis received a positive opinion from the CHMP in the EU.

                Neos Therapeutics ADHD Drug Adzenys Receives Approval in US

                Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.

                  Tirthankar Chakraborty headshot

                  S&P 500 Makes History, Steers Past 2500: Top 5 Gainers

                  The S&P 500, America's dominant stock market index, is in a 'breakout mode' right now as it powered past 2,500 for the first time

                    Pfizer Xtandi Succeeds in Early Stage Prostate Cancer Study

                    Pfizer's (PFE) prostate cancer drug Xtandi met the primary endpoint in a late-stage study, which can expand the label of the drug to include early-stage patients.

                      Amgen/Allergan's Avastin Biosimilar Secures FDA Approval

                      The FDA approves Amgen-Allergan's biosimilar version of Roche's Avastin for treating multiple types of cancers, to be marketed by the trade name of Mvasi.

                        AstraZeneca Sells Remaining Rights to its Anaesthetics Drugs

                        AstraZeneca (AZN) recently sold its remaining rights to its anaesthetics medicines to Aspen Group for an upfront consideration of $555 million.

                          Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx

                          Novartis' (NVS) Cosentyx showed robust skin clearance data over a period of five years in patients with moderate-to-severe plaque psoriasis.

                            Abbott's (ABT) FreeStyle Libre Gets UK Reimbursement Nod

                            Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest U.K. national reimbursement grant.

                              Integra Divests Assets to Natus, Paves Way for Codman Buyout

                              Integra LifeSciences' (IART) divestment of certain neurosurgery assets to Natus Medical is part of the company's agenda to meet closing conditions toward the Codman neurosurgery business buyout.

                                Achillion's HCV Partnership with J&J Terminated, Stock Falls

                                Achillion Pharmaceuticals (ACHN) suffered a setback as Janssen terminated their worldwide license and collaboration arrangement on hepatitis C.

                                  3 Excellent Dividend ETFs for Turbulent Times

                                  Consider these 3 Dividend ETFs for your portfolio to battle market uncertainty.

                                    Swarup Gupta headshot

                                    Dow 30 Stock Roundup: UTX to Buy Rockwell Collins, Merck Secures EU Keytruda Approval

                                    The Dow endured significant losses over a holiday-shortened trading week.

                                      MedTech Hangs in the Balance as Obamacare Skinny Repeal Fails

                                      Any retention or repeal of Obamacare will actually create a vicious circle within the MedTech sector.

                                        J&J (JNJ) PAH Drug's U.S. Label Expanded for Pediatric Use

                                        Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved a label expansion for its oral pulmonary arterial hypertension (PAH) medicine, Tracleer.

                                          The Zacks Analyst Blog Highlights: Johnson & Johnson, JPMorgan, Microsoft, Motorola, J.M. Smucker and Entergy

                                          The Zacks Analyst Blog Highlights: Johnson & Johnson, JPMorgan, Microsoft, Motorola, J.M. Smucker and Entergy

                                            Pfizer Presents Encouraging Eliquis Results in NVAF Patients

                                            Pfizer (PFE) and partner Bristol-Myers presented data on Eliquis which showed the potential of the drug in reducing stroke and systemic embolism in NVAF patients undergoing cardioversion.

                                              Biogen Alzheimer's Drug Shows Promise in Long-Term Study

                                              Biogen (BIIB) announced data from a long-term study on its Alzheimer's disease candidate, aducanumab, which showed continued benefit in the rate of amyloid decline.

                                                Company News For August 29, 2017

                                                Companies in the news are: EXPE,BIIB,GILD,KITE,JNJ

                                                  J&J's (JNJ) Xarelto/Aspirin Regimen Positive in Phase III

                                                  J&J's (JNJ) blood thinner Xarelto shows a significant risk reduction in major cardiovascular events in patients with stable coronary and peripheral artery disease.